

Title (en)
PROTEASE INHIBITORS

Title (de)
PROTEASEINHIBITOREN

Title (fr)
INHIBITEURS DE PROTEASE

Publication
EP 1231923 A1 20020821 (EN)

Application
EP 00983690 A 20001108

Priority
• US 0030702 W 20001108
• US 16457799 P 19991110

Abstract (en)
[origin: WO0134157A1] This invention relates to the compound of Formula (I): or a pharmaceutical acceptable salt, hydrate or solvate thereof, which is an inhibitor of cysteine proteases, particularly cathepsin K, and is useful in the treatment of diseases in which inhibition of bone loss or of cartilage degradation is a factor.

IPC 1-7
A61K 31/55; C07D 405/14; A61P 19/08; A61P 19/10

IPC 8 full level
A61K 31/55 (2006.01); **A61K 38/36** (2006.01); **A61K 45/06** (2006.01); **A61P 1/02** (2006.01); **A61P 3/14** (2006.01); **A61P 19/02** (2006.01); **A61P 19/08** (2006.01); **A61P 19/10** (2006.01); **A61P 21/00** (2006.01); **A61P 29/00** (2006.01); **A61P 33/02** (2006.01); **A61P 33/06** (2006.01); **A61P 33/08** (2006.01); **A61P 33/12** (2006.01); **A61P 35/04** (2006.01); **A61P 43/00** (2006.01); **C07D 405/14** (2006.01)

CPC (source: EP)
A61K 31/55 (2013.01); **A61P 1/02** (2017.12); **A61P 3/14** (2017.12); **A61P 19/02** (2017.12); **A61P 19/08** (2017.12); **A61P 19/10** (2017.12); **A61P 21/00** (2017.12); **A61P 29/00** (2017.12); **A61P 33/02** (2017.12); **A61P 33/06** (2017.12); **A61P 33/08** (2017.12); **A61P 33/12** (2017.12); **A61P 35/04** (2017.12); **A61P 43/00** (2017.12); **C07D 405/14** (2013.01); **Y02A 50/30** (2017.12)

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 0134157 A1 20010517; **WO 0134157 A9 20020510**; EP 1231923 A1 20020821; EP 1231923 A4 20030514; JP 2003513925 A 20030415

DOCDB simple family (application)
US 0030702 W 20001108; EP 00983690 A 20001108; JP 2001536155 A 20001108